Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Asmanex
2. Asmanex Twisthaler
3. Elocon
4. Furoate Monohydrate, Mometasone
5. Furoate, Mometasone
6. Mometasone
7. Mometasone Furoate Monohydrate
8. Monohydrate, Mometasone Furoate
9. Nasonex
10. Rinelon
11. Sch 32088
12. Sch-32088
13. Sch32088
14. Twisthaler, Asmanex
1. 83919-23-7
2. Asmanex
3. Nasonex
4. Elocon
5. Monovo
6. Sch 32088
7. Mometasone 17-furoate
8. Sinuva
9. Mometasone Furoate Anhydrous
10. Sch32088
11. Sch-32088
12. Nsc-746171
13. Chembl1161
14. Lyr210
15. (8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl Furan-2-carboxylate
16. [(8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Furan-2-carboxylate
17. Chebi:47564
18. Lyr-210
19. 04201gdn4r
20. Nsc-760077
21. (11beta,16alpha)-9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
22. Danitin
23. Ecural
24. Elomet
25. Dsstox_cid_3333
26. Asmanex Twisthaler
27. Dsstox_rid_76981
28. Dsstox_gsid_23333
29. (9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl Furan-2-carboxylate
30. 9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl Furan-2-carboxylate
31. Elocone
32. Flumeta
33. Nosorex
34. Rimelon
35. Ovixan
36. Asmanex Hfa
37. Mometasone Fuorate
38. Mof
39. Unii-04201gdn4r
40. Mometasone-furoate
41. Ncgc00016950-01
42. Prestwick_924
43. Asmanex (tn)
44. Mometasone Furoate [usan:usp:jan]
45. Cas-83919-23-7
46. Elocon (tn)
47. Las 41002
48. Brn 4340538
49. Prestwick0_000572
50. Prestwick1_000572
51. Prestwick2_000572
52. Prestwick3_000572
53. Mometasone Furancarboxylate
54. Schembl4568
55. Bspbio_000384
56. Mometasone 17-(2-furoate)
57. Mls002153879
58. Spbio_002603
59. Mometasone Furoate (jan/usp)
60. Bpbio1_000424
61. Mometasone Furoate [mi]
62. Dtxsid4023333
63. Mometasone Furoate [jan]
64. Mometasone Furoate [usan]
65. Hms1569d06
66. Hms2096d06
67. Hms2235i14
68. Hms3713d06
69. Mometasone Furoate [vandf]
70. Mometasone Furoate [mart.]
71. Mometasone Furoate [usp-rs]
72. Mometasone Furoate [who-dd]
73. Zinc3938677
74. Tox21_110705
75. Ac-941
76. Bdbm50148733
77. Mfcd00866003
78. Nsc746171
79. S1987
80. Mometasone Furoate, >=98% (hplc)
81. Akos015994732
82. Tox21_110705_1
83. Ccg-220572
84. Db14512
85. Ks-1275
86. Mometasone Furoate [green Book]
87. Nsc 746171
88. Nsc 760077
89. 9,21-dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
90. Mometasone Furoate [orange Book]
91. Mometasone Furoate [ep Monograph]
92. Ncgc00179578-01
93. Ncgc00179578-03
94. Ncgc00179578-04
95. (11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl Furan-2-carboxylate
96. Dulera Component Mometasone Furoate
97. Hy-13693
98. Mometasone Furoate [usp Monograph]
99. Smr001233233
100. M2354
101. Mometasone Furoate Component Of Dulera
102. C07817
103. D00690
104. Mometasone Furoate 1000 Microg/ml In Methanol
105. 919m237
106. A840685
107. Mometasone Furoate 100 Microg/ml In Acetonitrile
108. Sr-01000841209
109. Lyr-220 Active Component Mometasone Furoate
110. Q-101380
111. Q1044248
112. Sr-01000841209-2
113. Brd-k60640630-001-03-7
114. Brd-k60640630-001-11-0
115. Mometasone Furoate, European Pharmacopoeia (ep) Reference Standard
116. Mometasone Furoate, United States Pharmacopeia (usp) Reference Standard
117. 11?,16?)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
118. Mometasone Furoate, Pharmaceutical Secondary Standard; Certified Reference Material
119. (11.beta.,16.alpha.)-9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
120. [(8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Furan-2-carboxylate;mometasone Furoate
121. [(9r,10s,11s,13s,16r,17r)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Furan-2-carboxylate
122. 9,21-dichloro-11.beta.,17-dihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
123. Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-
124. Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)
125. Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-
| Molecular Weight | 521.4 g/mol |
|---|---|
| Molecular Formula | C27H30Cl2O6 |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 5 |
| Exact Mass | 520.1419441 g/mol |
| Monoisotopic Mass | 520.1419441 g/mol |
| Topological Polar Surface Area | 93.8 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 1020 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 6 | |
|---|---|
| Drug Name | Elocon |
| Drug Label | ELOCON (mometasone furoate) Ointment, 0.1% contains mometasone furoate for topical use. Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity.Chemically, mometasone furoate is 9,21-dichloro-11,17-dihydroxy-16-methylpr... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 2 of 6 | |
|---|---|
| Drug Name | Mometasone furoate |
| PubMed Health | Mometasone |
| Drug Classes | Anti-Inflammatory, Corticosteroid, Strong |
| Drug Label | Mometasone furoate, the active component of the ASMANEX TWISTHALER product, is a corticosteroid with the chemical name 9,21-dichloro-11(Beta),17-dihydroxy-16(alpha)-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) and the following chemical structure... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Ointment; Cream; Lotion |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Taro; Glenmark Generics; Fougera Pharms; Perrigo; Perrigo New York; Tolmar; G And W Labs |
| 3 of 6 | |
|---|---|
| Drug Name | Nasonex |
| Drug Label | Mometasone furoate monohydrate, the active component of NASONEX Nasal Spray, 50 mcg, is an anti-inflammatory corticosteroid having the chemical name, 9,21-Dichloro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione17-(2 furoate) monohydrate, an... |
| Active Ingredient | Mometasone furoate monohydrate |
| Dosage Form | Spray, metered |
| Route | Nasal |
| Strength | eq 0.05mg base/spray |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 4 of 6 | |
|---|---|
| Drug Name | Elocon |
| Drug Label | ELOCON (mometasone furoate) Ointment, 0.1% contains mometasone furoate for topical use. Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity.Chemically, mometasone furoate is 9,21-dichloro-11,17-dihydroxy-16-methylpr... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Lotion; Ointment; Cream |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 5 of 6 | |
|---|---|
| Drug Name | Mometasone furoate |
| PubMed Health | Mometasone |
| Drug Classes | Anti-Inflammatory, Corticosteroid, Strong |
| Drug Label | Mometasone furoate, the active component of the ASMANEX TWISTHALER product, is a corticosteroid with the chemical name 9,21-dichloro-11(Beta),17-dihydroxy-16(alpha)-methylpregna-1,4-diene-3,20-dione 17-(2-furoate) and the following chemical structure... |
| Active Ingredient | Mometasone furoate |
| Dosage Form | Ointment; Cream; Lotion |
| Route | Topical |
| Strength | 0.1% |
| Market Status | Prescription |
| Company | Taro; Glenmark Generics; Fougera Pharms; Perrigo; Perrigo New York; Tolmar; G And W Labs |
| 6 of 6 | |
|---|---|
| Drug Name | Nasonex |
| Drug Label | Mometasone furoate monohydrate, the active component of NASONEX Nasal Spray, 50 mcg, is an anti-inflammatory corticosteroid having the chemical name, 9,21-Dichloro-11,17-dihydroxy-16-methylpregna-1,4-diene-3,20-dione17-(2 furoate) monohydrate, an... |
| Active Ingredient | Mometasone furoate monohydrate |
| Dosage Form | Spray, metered |
| Route | Nasal |
| Strength | eq 0.05mg base/spray |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
There are 3 formulations of mometasone furoate with various indications. The inhaler is indicated for prophylaxis of asthma in patients 4 years. The nasal spray is indicated for treating nasal symptoms of allergic rhinitis in patients 2 years, treating symptoms of nasal congestion from seasonal allergic rhinitis in patients 2 years, treating nasal polyps in patients 18 years, and prophylaxis of seasonal allergic rhinitis in patients 12 years. The ointment is indicated for symptomatic treatment of dermatitis and pruritis in patients 2 years.
FDA Label
Seasonal and perennial allergic rhinitis
Mometasone is a synthetic corticosteroid with an affinity for glucocorticoid receptors 22 times higher than that of [dexamethasone]. Mometasone furoate also has a lower affinity to mineralocorticoid receptors than natural corticosteroids, making it more selective in its action. Mometasone furoate diffuses across cell membranes to activate pathways responsible for reducing inflammation.
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Dermatologic Agents
Drugs used to treat or prevent skin disorders or for the routine care of skin. (See all compounds classified as Dermatologic Agents.)
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Absorption
The mean time to peak concentration is 1.0 to 2.5 hours. Bioavailability has been reported as <1% but studies of repeat doses of inhaled corticosteroids suggest a bioavailability of 11%. The 0.1% ointment may have a bioavailability of 0.7%.
Route of Elimination
For an inhaled dose, approximately 74% is excreted in the feces and 8% is excreted in the urine.
Volume of Distribution
Steady state volume of distribution of 152L.
Clearance
The clearance rate of mometasone furoate is not readily available, though it may be close to 90L/h.
Metabolism of mometasone furoate is largely performed hepatically by cytochrome P450 3A4 producing a number of metabolites. Some of these metabolites include free mometasone and 6-beta-hydroxy-mometasone furoate.
The terminal half life of an inhaled dose is approximately 5 hours though it has been reported as 5.8 hours by other sources.
In asthma, mometasone is believed to inhibit mast cells, eosinophils, basophils, and lymphocytes. There is also evidence of inhibition of histamine, leukotrienes, and cytokines. Corticosteroids diffuse across cell membranes into the cytosol of cells where they bind to glucocorticoid receptors to produce their activity. Mometasone furoate has a particularly high receptor affinity compare to other corticosteroids, 22 times higher than that of [dexamethasone]. Mometasone furoate binding to a glucocorticoid receptor causes conformational changes in the receptor, separation from chaperones, and the receptor moves to the nucleus. Once at the nucleus, receptors dimerize and bind to a DNA sequence known as the glucocorticoid response element which either increases expression of anti-inflammatory molecules or inhibits expression of pro-inflammatory molecules (such as interleukins 4 and 5). Mometasone furoate also reduces inflammation by blocking transcription factors such as activator-protein-1 and nuclear factor kappa B (NF-kappaB).
API SUPPLIERS
Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
Click Us!
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-05-01
Pay. Date : 2014-04-29
DMF Number : 20684
Submission : 2007-07-12
Status : Active
Type : II
Certificate Number : R1-CEP 2007-194 - Rev 03
Issue Date : 2022-08-26
Type : Chemical
Substance Number : 1449
Status : Valid
Date of Issue : 2022-09-30
Valid Till : 2025-07-02
Written Confirmation Number : WC-0161
Address of the Firm :
NDC Package Code : 22552-0002
Start Marketing Date : 2017-12-12
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Coral's API range includes Corticosteroids, Antihistamines. Hormones and Antineoplastics.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30852
Submission : 2016-09-09
Status : Active
Type : II
Certificate Number : R0-CEP 2022-081 - Rev 00
Issue Date : 2023-05-26
Type : Chemical
Substance Number : 1449
Status : Valid
Date of Issue : 2022-09-16
Valid Till : 2025-07-05
Written Confirmation Number : WC-0009
Address of the Firm :
Axplora- The partner of choice for complex APIs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-12-09
Pay. Date : 2019-09-18
DMF Number : 33446
Submission : 2019-03-11
Status : Active
Type : II
Certificate Number : CEP 2018-297 - Rev 02
Issue Date : 2023-10-06
Type : Chemical
Substance Number : 1449
Status : Valid
NDC Package Code : 46439-8733
Start Marketing Date : 2008-12-12
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : SAU |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15187
Submission : 2000-12-07
Status : Active
Type : II
Certificate Number : R0-CEP 2021-233 - Rev 01
Issue Date : 2023-01-18
Type : Chemical
Substance Number : 2858
Status : Valid
NDC Package Code : 58175-0551
Start Marketing Date : 2009-02-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : EU DMF |
DKSH is your trusted partner for companies looking to grow their business in Asia & beyond.
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
Jai Radhe Sales is your partner for all your sourcing needs.
Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 21334
Submission : 2008-02-12
Status : Active
Type : II
Certificate Number : R1-CEP 2007-302 - Rev 03
Issue Date : 2022-10-14
Type : Chemical
Substance Number : 1449
Status : Valid
Date of Issue : 2023-01-06
Valid Till : 2025-07-29
Written Confirmation Number : WC-0099
Address of the Firm :
NDC Package Code : 15308-0220
Start Marketing Date : 2006-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Jinyoung Pharmaceutical Co., Ltd.
Registration Date : 2021-12-10
Registration Number : 20211210-211-J-1176
Manufacturer Name : Aarti Pharmalabs Limited
Manufacturer Address : Plot No. E-50, 50/1 & 59/1, Unit-IV, MIDC, Tarapur, Taluka & District - Palghar, 401 506, Maharashtra State, India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
QVM149 combines the bronchodilation of indacaterol acetate (a LABA) and the antimuscarinic effects of glycopyrronium bromide (a LAMA) with mometasone furoate in a precise once-daily formulation, delivered via the dose-confirming Breezhaler® device.
Lead Product(s): Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Enerzair Breezhaler
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
QVM149 Receives Regulatory Approval in Europe and Japan
Details : QVM149 combines the bronchodilation of indacaterol acetate (a LABA) and the antimuscarinic effects of glycopyrronium bromide (a LAMA) with mometasone furoate in a precise once-daily formulation, delivered via the dose-confirming Breezhaler® device.
Brand Name : Enerzair Breezhaler
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 07, 2020
Details:
LYR-210 (mometasone furoate) is a glucocorticoid receptor agonist. It is being evaluated as an anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Immunology Brand Name: LYR-210
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2024
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lyra Therapeutics Completes Enrollment in Phase 3 Trial for Chronic Rhinosinusitis
Details : LYR-210 (mometasone furoate) is a glucocorticoid receptor agonist. It is being evaluated as an anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis.
Brand Name : LYR-210
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2024
Details:
LYR-210 (mometasone furoate) is a glucocorticoid receptor agonist. It is being evaluated as an anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Infections and Infectious Diseases Brand Name: LYR-210
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2024
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210
Details : LYR-210 (mometasone furoate) is a glucocorticoid receptor agonist. It is being evaluated as an anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis.
Brand Name : LYR-210
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 06, 2024
Details:
Nasonex-Generic (mometasone furoate monohydrate) nasal spray, a corticosteroid, has received FDA approval for treating allergic rhinitis symptoms.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Immunology Brand Name: Nasonex-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aurobindo Receives USFDA Approval for Mometasone Furoate Nasal Spray
Details : Nasonex-Generic (mometasone furoate monohydrate) nasal spray, a corticosteroid, has received FDA approval for treating allergic rhinitis symptoms.
Brand Name : Nasonex-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 19, 2024
Details:
ESO-101 (mometasone furoate), designed as a locoregional, esophagus-adjusted drug formulation and novel delivery system to optimize mucosal contact time and maximize esophageal deposition, has the potential to provide significant clinical benefits to eosinophilic esophagitis.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Gastroenterology Brand Name: ESO-101
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ESO-101 (mometasone furoate), designed as a locoregional, esophagus-adjusted drug formulation and novel delivery system to optimize mucosal contact time and maximize esophageal deposition, has the potential to provide significant clinical benefits to eos...
Brand Name : ESO-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Details:
LYR-220 (mometasone furoate) is a bioresorbable, polymetric matrix that is designed to deliver six months of continuous anti-inflammatory medication (7500µg MF) to the sinonasal passages for the treatment of CRS.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LYR-220
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LYR-220 (mometasone furoate) is a bioresorbable, polymetric matrix that is designed to deliver six months of continuous anti-inflammatory medication (7500µg MF) to the sinonasal passages for the treatment of CRS.
Brand Name : LYR-220
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 12, 2023
Details:
ESO-101 was designed as a locoregional, esophagus-adjusted drug formulation and novel delivery system to optimize mucosal contact time and maximize esophageal deposition of mometasone furoate. it has the potential to provide significant clinical benefits to EoE patients.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Gastroenterology Brand Name: ESO-101
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EsoCap Completes Patient Recruitment in ACESO Phase II Trial in Eosinophilic Esophagitis
Details : ESO-101 was designed as a locoregional, esophagus-adjusted drug formulation and novel delivery system to optimize mucosal contact time and maximize esophageal deposition of mometasone furoate. it has the potential to provide significant clinical benefits...
Brand Name : ESO-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 05, 2023
Details:
LYR-210 (mometasone furoate) is a bioresorbable nasal implant which is intended to deliver up to six months of continuous, proven anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat chronic rhinosinusitis (CRS).
Lead Product(s): Mometasone Furoate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LYR-210
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LYR-210 (mometasone furoate) is a bioresorbable nasal implant which is intended to deliver up to six months of continuous, proven anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat chronic rhinosinusitis (CRS).
Brand Name : LYR-210
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 29, 2023
Details:
The financing will be used to complete company's pivotal clinical trials of LYR-210 (mometasone furoate), a bioresorbable nasal mesh, being developed in Phase 3 for chronic rhinosinusitis (CRS) patients.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: LYR-210
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Perceptive Advisors
Deal Size: $50 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 01, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Perceptive Advisors
Deal Size : $50 million
Deal Type : Private Placement
Lyra Therapeutics Announces Closing of $50.0 Million Private Placement
Details : The financing will be used to complete company's pivotal clinical trials of LYR-210 (mometasone furoate), a bioresorbable nasal mesh, being developed in Phase 3 for chronic rhinosinusitis (CRS) patients.
Brand Name : LYR-210
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 01, 2023
Details:
LYR-210 is a bioresorbable nasal implant which is intended to deliver up to six months of continuous, proven anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat chronic rhinosinusitis (CRS).
Lead Product(s): Mometasone Furoate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: LYR-210
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : LYR-210 is a bioresorbable nasal implant which is intended to deliver up to six months of continuous, proven anti-inflammatory therapy, mometasone furoate, to the sinonasal passages to treat chronic rhinosinusitis (CRS).
Brand Name : LYR-210
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 25, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Sweden
Brand Name : Mometasone Orion
Dosage Form : NÄSSPRAY, SUSPENSION
Dosage Strength : 50 MIKROGRAM/DOS
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Ukraine
Brand Name : Moleskin
Dosage Form : Ointment
Dosage Strength : 0.1%
Packaging : 15G Tube
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ukraine
Regulatory Info :
Registration Country : Switzerland
Indacaterolum; Glycopyrronium; Mometasoni-17 furoas
Brand Name : Enerzair Breezhaler Inha+Sens
Dosage Form : Inh Caps
Dosage Strength : 150/50/160Mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Brand Name : Elocom
Dosage Form : Cream
Dosage Strength : 0.10%
Packaging : Tube
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Mometasone furoate monohydrate
Brand Name : Nasonex
Dosage Form : Nasal spray, suspension
Dosage Strength : 50 microg/dose
Packaging : Plastic bottle with dose pump 120doses
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Sweden
Brand Name : Mometasone Teva
Dosage Form : NÄSSPRAY, SUSPENSION
Dosage Strength : 50 MIKROGRAM/DOS
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info : Generic
Registration Country : Turkey
Brand Name :
Dosage Form : METERED NASAL SPRAY, SUSPENSION
Dosage Strength : 50MCG
Packaging : 200 Doses/Bottle
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Turkey
Regulatory Info :
Registration Country : Sweden
Brand Name : Elocom
Dosage Form : KRÄM
Dosage Strength : 0,1 %
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Nasonex
Dosage Form :
Dosage Strength : 140 Doses Nasal Spray 50 Mcg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : Mometasone 0.1% Korhispana 60Ml Solution Cutan Efg
Dosage Form : Solution
Dosage Strength : 1 Mg/Solution
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Ointment
Dosage Strength : 0.1%/w/w
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Packaging :
Regulatory Info :
Dosage : Ointment
Dosage Strength : 0.1%/w/w
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Nasal Spray
Dosage Strength : 0.05%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Packaging :
Regulatory Info :
Dosage : Nasal Spray
Dosage Strength : 0.05%
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Romania
Brand Name : MOMETASONE Atb®
Dosage Form : Ointment
Dosage Strength : 1MG/G
Packaging : Box x 1 tube x 15 g
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Romania
Packaging : Box x 1 tube x 15 g
Regulatory Info :
Dosage : Ointment
Dosage Strength : 1MG/G
Brand Name : MOMETASONE Atb®
Approval Date :
Application Number :
Registration Country : Romania
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Aerosol, Metered
Dosage Strength : 0.1MG/INH
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Aerosol, Metered
Dosage Strength : 0.1MG/INH
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Aerosol, Metered
Dosage Strength : 0.2MG/INH
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Aerosol, Metered
Dosage Strength : 0.2MG/INH
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Mometasone Furoate; Terbinafine Hydrochloride
Brand Name : Terbizon
Dosage Form : Cream
Dosage Strength : 0.1%; 1%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Mometasone Furoate; Terbinafine Hydrochloride
Dosage : Cream
Dosage Strength : 0.1%; 1%
Brand Name : Terbizon
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : Glorocin-M
Dosage Form : Ointment
Dosage Strength : 2%; 0.1%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Ointment
Dosage Strength : 2%; 0.1%
Brand Name : Glorocin-M
Approval Date :
Application Number :
Registration Country : India
Regulatory Info : Generic
Registration Country : South Korea
Mometasone Furoate; azelastine hydrochloride
Brand Name : NASAFLEX
Dosage Form : NASAL SPRAY
Dosage Strength : 0.5MG; 1.4MG
Packaging : 18g, 1btl
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Korea
Packaging : 18g, 1btl
Regulatory Info : Generic
Mometasone Furoate; azelastine hydrochloride
Dosage : NASAL SPRAY
Dosage Strength : 0.5MG; 1.4MG
Brand Name : NASAFLEX
Approval Date :
Application Number :
Registration Country : South Korea
Regulatory Info : Generic
Registration Country : Malaysia
Brand Name : Vizomet
Dosage Form : CREAM
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Malaysia
Packaging :
Regulatory Info : Generic
Dosage : CREAM
Dosage Strength :
Brand Name : Vizomet
Approval Date :
Application Number :
Registration Country : Malaysia
Regulatory Info :
Registration Country : China
Brand Name :
Dosage Form : Cream
Dosage Strength : 5MG/5G
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China
Packaging :
Regulatory Info :
Dosage : Cream
Dosage Strength : 5MG/5G
Brand Name :
Approval Date :
Application Number :
Registration Country : China
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - OINTMENT;TOPICAL - 0.1%
USFDA APPLICATION NUMBER - 19543
DOSAGE - CREAM;TOPICAL - 0.1% **Federal Regis...DOSAGE - CREAM;TOPICAL - 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 19625
DOSAGE - LOTION;TOPICAL - 0.1% **Federal Regi...DOSAGE - LOTION;TOPICAL - 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 19796
DOSAGE - AEROSOL, METERED;INHALATION - 0.05MG...DOSAGE - AEROSOL, METERED;INHALATION - 0.05MG/INH
USFDA APPLICATION NUMBER - 205641
DOSAGE - AEROSOL, METERED;INHALATION - 0.10MG...DOSAGE - AEROSOL, METERED;INHALATION - 0.10MG/INH
USFDA APPLICATION NUMBER - 205641
DOSAGE - AEROSOL, METERED;INHALATION - 0.20MG...DOSAGE - AEROSOL, METERED;INHALATION - 0.20MG/INH
USFDA APPLICATION NUMBER - 205641
DOSAGE - SPRAY, METERED;NASAL - 0.05MG/SPRAY ...DOSAGE - SPRAY, METERED;NASAL - 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20762
DOSAGE - POWDER;INHALATION - 0.11MG/INH
USFDA APPLICATION NUMBER - 21067
DOSAGE - POWDER;INHALATION - 0.22MG/INH
USFDA APPLICATION NUMBER - 21067
DOSAGE - AEROSOL, METERED;INHALATION - 0.005M...DOSAGE - AEROSOL, METERED;INHALATION - 0.005MG/INH;0.05MG/INH
USFDA APPLICATION NUMBER - 22518
DOSAGE - AEROSOL, METERED;INHALATION - 0.005M...DOSAGE - AEROSOL, METERED;INHALATION - 0.005MG/INH;0.1MG/INH
USFDA APPLICATION NUMBER - 22518
DOSAGE - AEROSOL, METERED;INHALATION - 0.005M...DOSAGE - AEROSOL, METERED;INHALATION - 0.005MG/INH;0.2MG/INH
USFDA APPLICATION NUMBER - 22518
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Solubilizers
Thickeners and Stabilizers
Direct Compression
Parenteral
Coating Systems & Additives
Co-Processed Excipients
Topical
Film Formers & Plasticizers
Granulation
Disintegrants & Superdisintegrants
Rheology Modifiers
Emulsifying Agents
Controlled & Modified Release
Lubricants & Glidants
Taste Masking
Chewable & Orodispersible Aids
Surfactant & Foaming Agents
Coloring Agents
API Stability Enhancers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
